FABP3 and early-onset autosomal dominant Alzheimer disease: Conversely, in the meta-analysis by [27], using data from two clinical studies comprising healthy controls and Alzheimer’s disease patients, there was no relationship between the groups when serum hFABP was used as the biomarker for assessing vascular dysregulation.